medwireNews: The combination of lenvatinib and pembrolizumab has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use for the first-line treatment of advanced renal cell carcinoma (RCC).
This decision follows the positive results of the phase 3 CLEAR trial, which showed a significant progression-free and overall survival benefit with use of lenvatinib plus pembrolizumab relative to sunitinib.
Advertisement
The combination of the multikinase inhibitor plus the PD-1 inhibitor was approved for the same indication by the US FDA earlier this year.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group